LEADER 01705nam 2200433 a 450 001 9910698226703321 005 20061220162744.0 035 $a(CKB)4970000000037347 035 $a(OCoLC)77140869 035 $a(EXLCZ)994970000000037347 100 $a20061220d2006 ua 0 101 0 $aeng 135 $aurmn|---||||| 181 $ctxt$2rdacontent 182 $cc$2rdamedia 183 $acr$2rdacarrier 200 10$aInternal control$b[electronic resource] $eanalysis of joint study on estimating the costs and benefits of rendering opinions on internal control over financial reporting in the federal environment 210 1$aWashington, DC :$cU.S. Government Accountability Office,$d[2006] 215 $a44 pages $cdigital, PDF file 300 $aTitle from title screen (viewed on Dec. 11, 2006). 300 $aAuthor: McCoy Williams. 300 $a"September 6, 2006." 300 $aPaper version available from: U.S. Government Accountability Office, 441 G St., NW, Rm. LM, Washington, D.C. 20548. 300 $a"GAO-06-255R." 320 $aIncludes bibliographical references. 517 $aInternal Control 606 $aAdministrative agencies$zUnited States$xAccounting 606 $aAuditing, Internal$xEconomic aspects$zUnited States 607 $aUnited States$xAppropriations and expenditures$xAuditing 615 0$aAdministrative agencies$xAccounting. 615 0$aAuditing, Internal$xEconomic aspects 700 $aWilliams$b McCoy$01380698 712 02$aUnited States.$bGovernment Accountability Office. 801 0$bGPO 801 1$bGPO 906 $aDOCUMENT 912 $a9910698226703321 996 $aInternal control$93512025 997 $aUNINA LEADER 04343nam 2200697 450 001 9910815740203321 005 20230801234717.0 010 $a1-62637-336-1 024 7 $a10.1515/9781626373365 035 $a(CKB)3710000000466065 035 $a(EBL)4352968 035 $a(SSID)ssj0001544234 035 $a(PQKBManifestationID)16135041 035 $a(PQKBTitleCode)TC0001544234 035 $a(PQKBWorkID)14334109 035 $a(PQKB)11328152 035 $a(MiAaPQ)EBC4352968 035 $a(Au-PeEL)EBL4352968 035 $a(CaPaEBR)ebr11150312 035 $a(OCoLC)936881035 035 $a(DE-B1597)623582 035 $a(DE-B1597)9781626373365 035 $a(EXLCZ)993710000000466065 100 $a20160209h20122012 uy 0 101 0 $aeng 135 $aur|n|---||||| 181 $ctxt 182 $cc 183 $acr 200 10$aDriving down the cost of drugs $ebattling big pharma in the statehouse /$fRamo?n Castellblanch 210 1$aBoulder, Colorado ;$aLondon, [England] :$cFirstForumPress,$d2012. 210 4$d©2012 215 $a1 online resource (186 p.) 300 $aDescription based upon print version of record. 311 $a1-935049-45-3 320 $aIncludes bibliographical references and index. 327 $aTitle page; copyright page; Dedication; Contents; Preface; Acknowledgments; ch1-David, Goliath, and Prescription Drugs; ch2-How Drugs Got So Expensive; Getting Patent Privileges; Making the FDA a Partner and the Rise of the Blockbusters; Fighting Government Oversight and Exploiting the Blockbusters; The Blockbusters' Toll on America; ch3-Vermont Raises the Cry; The Road to S 300; 1999; S 300; Epilogue; ch4-As Goes Maine; Maine Background; Low-cost Drugs for the Elderly; Senate Leadership Commitments to Supporting Price Controls; Leinonen; Northeast Legislators; LD 2599; Industry Response 327 $aPublic Support to the RescueKing-Pingree Negotiations; Maine Rx; PhRMA v. Concannon; Maine Rx Plus; Postscript; ch5-PhRMA Tries Stopping State Action; PhRMA Political Spending in the Early 2000s; Post-Maine Rx State and Local Legislation; PhRMA's Turn to Congress; Industry Building Its Economic Power; Advocates' Continued Fighting after Part D; ch6-So Goes California; California Overview; 1999-2003; 2004: Legislative Leadership Taking the Stage; The Rise of Tension between the Governor and Legislative Leadership; 2005; 2006; Making a Deal; Implementation Delayed 327 $ach7-Politically Organizing for Access to MedicinesHearing Voters' Righteous Indignation; Allying with Powerful Progressive Organizations; Politically Isolating the Pharmaceutical Industry; "Framing" after Righteous Indignation; Inferences beyond Fighting for Medicines; Implications for US Health Policy; Appendix: Useful Websites on Health Care Policy and Politics; Bibliography; Index; About the Book 330 $aHow can health-access advocates beat the wealthy pharmaceutical industry, which has the biggest spending lobby in Washington? Ramón Castellblanch provides a ringside seat at the battle as he reveals how activists in Vermont, Maine, and California took on Big Pharma in their state legislatures to promote better and cheaper access to prescription drugs?and ultimately pushed Congress to enact a Medicare prescription drug benefit. He also draws lessons from these cases about the possibilities for success elsewhere in the health policy arena, highlighting the crucial role that voters' righteous indignation plays in fueling popular support for grassroots political leaders who are taking on powerful business interests. 606 $aPrescription pricing$zCalifornia 606 $aPrescription pricing$zMaine 606 $aPrescription pricing$zVermont 606 $aDrugs$xPrices$zCalifornia 606 $aDrugs$xPrices$zMaine 606 $aDrugs$xPrices$zVermont 615 0$aPrescription pricing 615 0$aPrescription pricing 615 0$aPrescription pricing 615 0$aDrugs$xPrices 615 0$aDrugs$xPrices 615 0$aDrugs$xPrices 676 $a368.38/24 700 $aCastellblanch$b Ramo?n$f1948-$01686469 801 0$bMiAaPQ 801 1$bMiAaPQ 801 2$bMiAaPQ 906 $aBOOK 912 $a9910815740203321 996 $aDriving down the cost of drugs$94059360 997 $aUNINA